Industry Verticals »

All Categories

Insights »

About TMR »

Erectile Dysfunction (ED) Drugs Market

Erectile Dysfunction (ED) Drugs Market (Drug: Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and Others; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Erectile Dysfunction (ED) Drugs Market Outlook 2028

  • The global erectile dysfunction drugs market was valued at US$ 3.4 Bn in 2020
  • It is estimated to incur value growth at a CAGR of -3.1% from 2021 to 2028
  • The global erectile dysfunction (ED) drugs industry is expected to reach the value of US$ 2.5 Bn by the end of 2028

Erectile Dysfunction Drugs Market: Overview

  • According to Transparency Market Research’s latest report on the global market for erectile dysfunction (ED) drugs for the historical period 2017–2019 and forecast period 2021–2028, some factors that drive the global market for erectile dysfunction (ED) drugs include the adoption of a sedentary lifestyle and its associated stress, rising geriatric population, and comorbidity between erectile dysfunction and heart disease and diabetes

Increase in Awareness and Patient Education: Key Driver

  • Educating patients on the appropriate use of erectile dysfunction drugs can be effective through initial education and focusing on the method of administration of drugs. For instance, sildenafil and vardenafil should be taken an hour before intercourse, and food and alcohol intake should be avoided, thereby maintaining the speed and extent of drug absorption. Both drugs are active for four to six hours. Tadalafil has the advantage of long duration of action i.e., for up to 36 hours. The absorption of tadalafil is unaffected by food and alcohol and the intake of tadalafil is advised several hours before sexual activity. Moreover, adequate sexual stimulation, ideally with a partner, is required.
  • Promotional and awareness campaigns for ED drugs should be extensively conducted to help minimize the stigma of impotence by bringing it out onto open discussion forums
  • Companies are working on educating the general population and people at risk, and advocating lifestyle changes
  • Pharmacists assess the needs of patients and identify drug problems to manage medication therapy

Narrowing of Insurance Coverage for Erectile Dysfunction Treatment

  • Development of pharmaceutical and branded drugs incur large investments and longer duration of time in R&D activities and making them available to the patients for the treatment
  • Modifications in healthcare insurance coverage can significantly affect the drug market. If an insurance program changes its policies and removes coverage for a certain treatment, sales of related drugs are likely to decrease. In general, insurance programs are more likely to cover essential expenses, such as heart disease medication, and are less likely to cover nonessential expenses, such as cosmetic surgery. The type of treatment prescribed for erectile dysfunction decides the possibility of insurance coverage. A person with a documented medical condition responsible for the cause of erectile dysfunction could incur insurance benefits. However, sex therapies and medications that have not been approved by the FDA have not been covered under insurance.
  • Due to its low dynamic nature, the trend of switching to new drugs or automatic substitution is not prevalent in the erectile dysfunction drugs market, thereby creating further hurdles for players willing to enter the market

Erectile Dysfunction (ED) Drugs Industry: Competition Landscape

  • This report profiles major players in the global ED drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global erectile dysfunction drugs market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global erectile dysfunction (ED) drugs market are
    • Pfizer, Inc.
    • Dong-A ST Co., Ltd.
    • Eli Lilly and Company
    • Bayer AG
    • Vivus, Inc.
    • Teva Pharmaceutical Industries Ltd.
  • Manufacturers are launching new products in the international market to tap the unmet needs of erectile dysfunction
  • Other prominent players operating in the global market include SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Futura Medical plc.

Erectile Dysfunction (ED) Drugs Market: Key Developments

  • Key players in the global erectile dysfunction (ED) drugs business are expanding their market position by adopting various strategies such as mergers & acquisitions and research collaborations with other companies to launch innovative products and consolidate their market positions across the world. A few expansion strategies adopted by players operating in the global erectile dysfunction drugs market are:
    • In December 2020, Glenmark Pharma received the final approval from the U.S. health regulator for Tadalafil tablets, which are used to treat erectile dysfunction and enlarged prostate
    • In June 2020, Launch Medical and GAINSWave announced the resolution of their lawsuit and started working together to market their revolutionary home-use acoustic wave device called The Phoenix for the treatment of erectile dysfunction
  • The report on the global erectile dysfunction (ED) drugs market discusses individual strategies, followed by company profiles of manufacturers of medical device technology products. The competition landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global market for erectile dysfunction (ED) drugs.

Erectile Dysfunction (ED) Drugs Market Snapshot

Attribute Detail
Market Size Value in 2020 US$ 3.4 Bn
Market Forecast Value in 2028 US$ 2.5 Bn
Growth Rate (CAGR) (3.1)%
Forecast Period 2021-2028
Quantitative Units US$ Bn for Value
Market Analysis It includes cross-segment analysis at the global as well as regional levels. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and a parent industry overview.
Competition Landscape
  • Market Player - Competition Matrix (by tier and size of companies)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Drug
    • Viagra
    • Cialis
    • Staxyn/Levitra
    • Stendra/Spedra
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • Pfizer, Inc.
  • Dong-A ST Co., Ltd.
  • Eli Lilly and Company
  • Bayer AG
  • Vivus, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • SK Chemicals
  • Meda Pharmaceuticals, Inc.
  • Cristalia Produtos Quimicos Farmaceuticos Ltda. Apricus Biosciences, Inc.
  • Futura Medical plc
  • Other prominent players
Customization Scope Available upon request
Pricing Available upon request

Note: Brackets for CAGR represent negative value.

Erectile Dysfunction (ED) Drugs Market - Segmentation

Attribute Detail
Drug
  • Viagra
  • Cialis
  • Staxyn/Levitra
  • Stendra/Spedra
  • Others
Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of erectile dysfunction (ED) drugs market?

The global erectile dysfunction drugs market was worth US$ 3.4 Bn and is projected to reach a value of US$ 2.5 Bn by the end of 2028

What is the anticipated CAGR of the global market for erectile dysfunction drugs in the forecast period?

The erectile dysfunction (ED) drugs market is anticipated to grow at a CAGR of -3.1% during the forecast period

Which region is expected to project the highest market share in the global erectile dysfunction drugs market?

North America accounted for a major share of the global erectile dysfunction (ED) drugs market

What are the key driving factors for the growth of the erectile dysfunction (ED) drugs business?

The market for erectile dysfunction (ED) drugs is being driven by factors such as the adoption of a sedentary lifestyle and the stress that comes with it, the growing geriatric population, and the comorbidity of erectile dysfunction with heart disease and diabetes. 

Who are the key players in the global erectile dysfunction (ED) drugs industry?

Key players in the global erectile dysfunction drugs market include Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, Vivus, Inc., and Teva Pharmaceutical Industries Ltd

    1. Preface

        1.1. Market Segmentation

        1.2. Key Research Objectives

        1.3. Research Highlights

    2. Assumptions and Research Methodology

        2.1. Secondary Research Methodology

        2.2. Primary Research Methodology

        2.3. Analysis Research Methodology

    3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Drug Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

    5. Market Outlook

        5.1. Market Dynamics

            5.1.1. Drivers

            5.1.2. Restraints

            5.1.3. Opportunity

            5.1.4. Opportunity Analysis

            5.1.5. Trends

        5.2. Global Erectile Dysfunction Market Analysis and Forecast, 2018-2028

        5.3. Porter’s Five Forces Analysis

        5.4. Erectile Dysfunction Drugs Market Value Chain Analysis

        5.5. Pipeline Analysis

            5.5.1. Discovery

            5.5.2. Preclinical

            5.5.3. IND (Investigational New Drug)

            5.5.4. Phase I

            5.5.5. Phase I/II

            5.5.6. Phase II

            5.5.7. Phase III

            5.5.8. Pre-registration

        5.6. Global Erectile Dysfunction (ED) Drug Market Outlook

    6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Drug

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Drug, 2018-2028

            6.3.1. Viagra

            6.3.2. Cialis

            6.3.3. Staxyn/Levitra

            6.3.4. Stendra/Spedra

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Drug

    7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Distribution Channel

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast, by Distribution Channel, 2018-2028

            7.3.1. Hospital Pharmacies

            7.3.2. Retail Pharmacies

            7.3.3. Online Pharmacies

        7.4. Market Attractiveness Analysis, by Distribution Channel

    8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Drug, 2018-2028

            9.2.1. Viagra

            9.2.2. Cialis

            9.2.3. Staxyn/Levitra

            9.2.4. Stendra/Spedra

            9.2.5. Others

        9.3. Market Value Forecast, by Distribution Channel, 2018-2028

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Value Forecast, by Country, 2018-2028

            9.4.1. U.S.

            9.4.2. Canada

    10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Drug, 2018-2028

            10.2.1. Viagra

            10.2.2. Cialis

            10.2.3. Staxyn/Levitra

            10.2.4. Stendra/Spedra

            10.2.5. Others

        10.3. Market Value Forecast, by Distribution Channel, 2018-2028

            10.3.1. Hospital Pharmacies

            10.3.2. Retail Pharmacies

            10.3.3. Online Pharmacies

        10.4. Market Value Forecast, by Country/Sub-region, 2018-2028

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

    11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Drug, 2018-2028

            11.2.1. Viagra

            11.2.2. Cialis

            11.2.3. Staxyn/Levitra

            11.2.4. Stendra/Spedra

            11.2.5. Others

        11.3. Market Value Forecast, by Distribution Channel, 2018-2028

            11.3.1. Hospital Pharmacies

            11.3.2. Retail Pharmacies

            11.3.3. Online Pharmacies

        11.4. Market Value Forecast, by Country/Sub-region, 2018-2028

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

    12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Drug, 2018-2028

            12.2.1. Viagra

            12.2.2. Cialis

            12.2.3. Staxyn/Levitra

            12.2.4. Stendra/Spedra

            12.2.5. Others

        12.3. Market Value Forecast, by Distribution Channel, 2018-2028

            12.3.1. Hospital Pharmacies

            12.3.2. Retail Pharmacies

            12.3.3. Online Pharmacies

        12.4. Market Value Forecast, by Country/Sub-region, 2018-2028

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

    13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Drug, 2018-2028

            13.2.1. Viagra

            13.2.2. Cialis

            13.2.3. Staxyn/Levitra

            13.2.4. Stendra/Spedra

            13.2.5. Others

        13.3. Market Value Forecast, by Distribution Channel, 2018-2028

            13.3.1. Hospital Pharmacies

            13.3.2. Retail Pharmacies

            13.3.3. Online Pharmacies

        13.4. Market Value Forecast, by Country/Sub-region, 2018-2028

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

    14. Competition Landscape

        14.1. Market Player - Competition Matrix (by tier and size of companies)

        14.2. Market Share Analysis, by Company, 2020

        14.3. Competitive Business Strategies

        14.4. Company Profiles

            14.4.1. Pfizer, Inc.

                14.4.1.1. Company Overview (HQ, Business Segments, Employee)

                14.4.1.2. Product Portfolio

                14.4.1.3. SWOT Analysis

                14.4.1.4. Strategic Overview

            14.4.2. Dong-A ST Co., Ltd.

                14.4.2.1. Company Overview (HQ, Business Segments, Employee)

                14.4.2.2. Product Portfolio

                14.4.2.3. SWOT Analysis

                14.4.2.4. Strategic Overview

            14.4.3. Eli Lilly and Company

                14.4.3.1. Company Overview (HQ, Business Segments, Employee)

                14.4.3.2. Product Portfolio

                14.4.3.3. SWOT Analysis

                14.4.3.4. Strategic Overview

            14.4.4. Bayer AG

                14.4.4.1. Company Overview (HQ, Business Segments, Employee)

                14.4.4.2. Product Portfolio

                14.4.4.3. SWOT Analysis

                14.4.4.4. Strategic Overview

            14.4.5. VIVUS, INC.

                14.4.5.1. Company Overview (HQ, Business Segments, Employee)

                14.4.5.2. Product Portfolio

                14.4.5.3. SWOT Analysis

                14.4.5.4. Strategic Overview

            14.4.6. SK chemicals

                14.4.6.1. Company Overview (HQ, Business Segments, Employee)

                14.4.6.2. Product Portfolio

                14.4.6.3. SWOT Analysis

                14.4.6.4. Strategic Overview

            14.4.7. Meda Pharmaceuticals, Inc.

                14.4.7.1. Company Overview (HQ, Business Segments, Employee)

                14.4.7.2. Product Portfolio

                14.4.7.3. SWOT Analysis

                14.4.7.4. Strategic Overview

            14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.

                14.4.8.1. Company Overview (HQ, Business Segments, Employee)

                14.4.8.2. Product Portfolio

                14.4.8.3. SWOT Analysis

                14.4.8.4. Strategic Overview

            14.4.9. Apricus Biosciences, Inc.

                14.4.9.1. Company Overview (HQ, Business Segments, Employee)

                14.4.9.2. Product Portfolio

                14.4.9.3. SWOT Analysis

                14.4.9.4. Strategic Overview

            14.4.10. Teva Pharmaceutical Industries Ltd.

                14.4.10.1. Company Overview (HQ, Business Segments, Employee)

                14.4.10.2. Product Portfolio

                14.4.10.3. SWOT Analysis

                14.4.10.4. Strategic Overview

    List of Tables

    Table 01: Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

    Table 02: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

    Table 03: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2018-2028

    Table 04: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2018-2028

    Table 05: North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

    Table 06: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

    Table 07: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028

    Table 08: Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

    Table 09: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

    Table 10: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028

    Table 11: Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

    Table 12: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

    Table 13: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028

    Table 14: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

    Table 15: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

    Table 16: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018-2028

    Table 17: Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2018-2028

    Table 18: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2018-2028

    Table 19: Pfizer, Inc. Products Offered

    Table 20: Pfizer, Inc. Recent Developments

    Table 21: Dong-A ST Co., Ltd. Products Offered

    Table 22: Dong-A ST Co., Ltd. Recent Developments

    Table 23: Eli Lilly and Company Products Offered

    Table 24: Eli Lilly and Company Recent Developments

    Table 25: Bayer AG Products Offered

    Table 26: Bayer AG Recent Developments

    Table 27: VIVUS, INC. Ltd. Products Offered

    Table 28: VIVUS, INC. Recent Developments

    Table 29: SK chemicals Products Offered

    Table 30: SK chemicals Recent Developments

    Table 31: Meda Pharmaceuticals Inc. Products Offered

    Table 32: Meda Pharmaceuticals Inc. Recent Developments

    Table 33: Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered

    Table 34: Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments

    Table 35: Apricus Biosciences, Inc. Products Offered

    Table 36: Apricus Biosciences, Inc. Recent Developments

    Table 37: Teva Pharmaceutical Industries Ltd. Products Offered

    List of Figures

    Figure 01: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, 2020-2028

    Figure 02: Market Value Share, by Drug Class (2020)

    Figure 03: Market Value Share, by Distribution Channel (2020)

    Figure 04: Market Value Share, by Region (2020)

    Figure 05: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

    Figure 06: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Viagra, 2020-2028

    Figure 07: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Cialis, 2020-2028

    Figure 08: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Staxyn/Levitra, 2020-2028

    Figure 09: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Stendra/Spedra, 2020-2028

    Figure 10: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by others, 2020-2028

    Figure 11: Global Erectile Dysfunction (ED) Drug Market Value Share Analysis, by Distribution channel, 2020 and 2028

    Figure 12: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2020-2028

    Figure 13: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2020-2028

    Figure 14: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacies, 2020-2028

    Figure 15: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Region, 2020 and 2028

    Figure 16: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2020-2028

    Figure 17: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country, 2020 and 2028

    Figure 18: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

    Figure 19: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

    Figure 20: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028

    Figure 21: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 22: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

    Figure 23: Europe Erectile Dysfunction (ED) Drugs Treatment Market Value Share Analysis, by Distribution Channel, 2020 and 2028

    Figure 24: Asia Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028

    Figure 25: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 26: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2020 and 2028

    Figure 27: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

    Figure 28: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028

    Figure 29: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 30: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2020 and 2028

    Figure 31: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

    Figure 32: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2028

    Figure 33: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 34: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2020 and 2028

    Figure 35: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2028

    Figure 36: Global Erectile Dysfunction (ED) Drugs Market Share Analysis, by Company (2020)

    Figure 37: Pfizer, Inc. Breakdown of Net Sales, by Region, 2020

    Figure 38: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2018-2020

    Figure 39: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018-2028

    Figure 40: Dong-A ST Co., Ltd. Breakdown of Net Sales, by Businesses Segment

    Figure 41: Dong-A ST Co., Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020

    Figure 42: Dong-A ST Co., Ltd. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018-2028

    Figure 43: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020

    Figure 44: Eli Lilly and Company R&D Intensity and Sales & Marketing Intensity – Company Level, 2018-2028

    Figure 45: Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2020

    Figure 46: Eli Lilly and Company Breakdown of Net Sales, (by Endocrinology Level), 2020

    Figure 47: Bayer AG Breakdown of Net Sales, by Region, 2020

    Figure 48: Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020

    Figure 49: Bayer AG R&D Intensity and Net Income (US$ Mn) – Company Level, 2020

    Figure 50: VIVUS, INC. R&D Intensity and Sales & Marketing Intensity – Company Level, 2018-2028

    Figure 51: VIVUS, INC. Breakdown of Revenue, by Operation (Company Level), 2020

    Figure 52: VIVUS, INC. Breakdown of Research and Development Expenses, 2020

    Figure 53: SK chemicals Consolidated Balance Sheet (US$ Bn), 2020

    Figure 54: SK chemicals Revenue (US$ Bn) and Y-o-Y Growth (%), 2018-2020

    Figure 55: SK chemicals R&D Intensity and Net Income (US$ Mn) – Company Level, 2018-2020

    Figure 56: Meda Pharmaceuticals Inc. Breakdown of Net Sales, by Region, 2020

    Figure 57: Meda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020

    Figure 58: Meda Pharmaceuticals Inc. Selling, Medicine &business development and administrative expenses (US$ Mn) – Company Level, 2018-2020

    Figure 59: Apricus Biosciences, Inc. Breakdown of Net Sales, by Region, 2020

    Figure 60: Apricus Biosciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2020

    Figure 61: Apricus Biosciences, Inc. R&D and General & administrative (US$ Mn) – Company Level, 2018-2028

    Figure 62: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2018-2020

    Figure 63: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2018-2028

    Figure 64: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2020

    Figure 65: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2020

Copyright © Transparency Market Research, Inc. All Rights reserved

Erectile Dysfunction (ED) Drugs Market

Schedule a Call